A pharmacokinetic and bioequivalence study of adalimumab biosimilar (CHS-1420)
Phase of Trial: Phase I
Latest Information Update: 28 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- 28 Aug 2017 Results published in a Coherus Biosciences Media Release.
- 02 Mar 2017 Results published in a Coherus Biosciences media release.
- 02 Mar 2017 Primary endpoint (Area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf)) has been met, according to a Coherus Biosciences media release.